 GenFleet Therapeutics has granted GFH009 rights to SELLAS Life Sciences Group Inc NASDAQ: SLS across all therapeutic and diagnostic uses worldwide outside of Greater China mainland China, Hong Kong, Macau, and Taiwan. GFH009 is a highly selective small-molecule cyclin. 